venBio Partners LLC Long-Term Concentrated

CIK: 0001776382 · Show all filings

Period: Q4 2023 (← Previous) (Next →)

Filing Date: Feb 14, 2024

Total Value ($000): $667,195 (100.0% shares, 0.0% debt)

Holdings (7)

— RAYZEBIO INC 48.1%

Value ($000) $320,683 Shares 5,158,162 Est. Cost $22.20 Unrealized —

ALXO ALX ONCOLOGY HLDGS INC 21.6%

Value ($000) $144,432 Shares 9,699,925 Est. Cost $39.31 Unrealized -75.9%

PHVS PHARVARIS N V 20.7%

Value ($000) $137,992 Shares 4,919,504 Est. Cost $21.15 Unrealized -4.3%

HRMY HARMONY BIOSCIENCES HLDGS IN 5.0%

Value ($000) $33,443 Shares 1,035,396 Est. Cost $36.46 Unrealized -23.4%

— ACELYRIN INC 4.3%

Value ($000) $28,739 Shares 3,852,470 Est. Cost $20.90 Unrealized —

— ELEVATION ONCOLOGY INC 0.2%

Value ($000) $1,565 Shares 2,914,255 Est. Cost $9.24 Unrealized —

— IMPEL PHARMACEUTICALS INC 0.1%

Value ($000) $341 Shares 2,759,791 Est. Cost $8.85 Unrealized —

Ticker	Issuer	Shares	Value ($000)	%	Est. Cost	Unrealized	Class	CUSIP
—	RAYZEBIO INC	5,158,162	$320,683	48.1%	$22.20	—	COM	75525N107
ALXO	ALX ONCOLOGY HLDGS INC	9,699,925	$144,432	21.6%	$39.31	-75.9%	COM	00166B105
PHVS	PHARVARIS N V	4,919,504	$137,992	20.7%	$21.15	-4.3%	COM	N69605108
HRMY	HARMONY BIOSCIENCES HLDGS IN	1,035,396	$33,443	5.0%	$36.46	-23.4%	COM	413197104
—	ACELYRIN INC	3,852,470	$28,739	4.3%	$20.90	—	COM	00445A100
—	ELEVATION ONCOLOGY INC	2,914,255	$1,565	0.2%	$9.24	—	COM	28623U101
—	IMPEL PHARMACEUTICALS INC	2,759,791	$341	0.1%	$8.85	—	COM	45258K109